Drug intelligence / Profile preview

enzalutamide + exemestane

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of enzalutamide, an androgen receptor inhibitor, and exemestane, an aromatase inhibitor. This combination targets both androgen and estrogen signaling pathways in hormone receptor-positive breast cancer. Due to enzalutamide's induction of CYP3A4, which reduces exemestane exposure by approximately 40-50%, the exemestane dose is typically doubled from 25 mg to 50 mg when used in this combination.

Targets

AR (Adrenergic receptors)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on enzalutamide + exemestane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on enzalutamide + exemestane.

Explore the full profile